CLL Coverage from Every Angle

Jennifer R. Brown, MD, PhD, on BTK Inhibitors: Zanubrutinib, Ibrutinib, Acalabrutinib in CLL/SLL

Posted: Monday, September 23, 2019

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses trials studying the potential risks and benefits of zanubrutinib, ibrutinib, and acalabrutinib in the treatment of patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.